Three complaints get the same answer more than any others: glare that takes too long to clear, floaters that will not settle, and the slow loss of detail at distance. The answer is that this is a normal part of aging and there is nothing to be done.
The answer is not wrong. It is incomplete in a specific way. It describes a category the symptom belongs to, and stops. Patients hear a description of a category as a refusal to look.
In forums where people describe these appointments, the same phrases repeat: they shrugged it off, you'll get used to it, there's nothing they can do. Alongside them, just as often, a quote for coatings the patient did not ask for.
Reporting in Australia in 2026 described optometrists at large chains under pressure to hit sales targets, with staff saying they were told to push for sales even where a prescription had not changed. That context does not make anyone dishonest. It does explain why a patient can leave an appointment feeling like a customer.
“Common is a description of how many people it happens to. It is not an explanation of what is happening.”
The study almost nobody gets shown
It is called the Alienor study, run in Bordeaux. Not a laboratory and not mice. Ordinary older people, mean age near eighty, followed over years. What they measured was esterified 3-hydroxy fatty acids in blood, used as a proxy for how much bacterial endotoxin a body is carrying.
Their finding, published in Investigative Ophthalmology & Visual Science: participants with higher levels of that marker had a higher rate of developing early age-related macular degeneration. The hazard ratio was 1.21 for each standard deviation of increase, and it held after adjusting for age and sex.
Here is the other half, because a page that only quotes the flattering number does not deserve to be believed. The same study found no significant association with advanced macular degeneration. The authors say plainly that only randomized clinical trials can prove that one thing causes the other. This is an association in one cohort of very old French adults. It is not proof.
The limits are worth stating twice. This is one cohort, in one country, in a very old age group. The association was with early disease and not advanced disease. Observational work of this kind cannot establish that one thing causes another, and the authors say so themselves. Anyone selling certainty off the back of it is going beyond what it shows.
